{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-088247","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.788365+00:00","generated_at":"2026-05-31T14:28:56.019228+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"SAB Biotherapeutics appoints Lucy To as CFO effective August 12, 2024","bullets":["Lucy To appointed CFO; Mark Conley reassumes VP Finance role effective August 12.","To brings 18+ years experience; most recently MD at Wells Fargo Healthcare IB.","Employment agreement: $475K base, $125K signing bonus, 125K stock options vesting over 4 years.","Top-line Phase 1 data for T1D drug SAB-142 expected by end of 2024 per press release."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-088247","json":"https://secwatch.observer/filing/0000950170-24-088247.json","markdown":"https://secwatch.observer/filing/0000950170-24-088247.md","text":"https://secwatch.observer/filing/0000950170-24-088247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024088247/0000950170-24-088247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024088247/sabs-20240726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:28:56.019228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"369c230377","claim":"Lucy To was appointed as Chief Financial Officer at SAB Biotherapeutics, Inc..","evidence_excerpt":"On July 26, 2024, Lucy To, 38, was appointed Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (“SAB BIO” or the “Company”), with a start date of August 12, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024088247/0000950170-24-088247-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}]},{"claim_id":"8cf1e5519b","claim":"Mark Conley changed role as Vice President of Finance at SAB Biotherapeutics, Inc..","evidence_excerpt":"Mark Conley, who has been serving as Interim Chief Financial Officer since June 4, 2024, will reassume his prior position as the Company’s Vice President of Finance.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024088247/0000950170-24-088247-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"reassume"},{"label":"Role","value":"Vice President of Finance"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}